471 patents
Page 14 of 24
Utility
Kras G12C Inhibitors
2 Sep 21
The present invention relates to compounds that inhibit KRas G12C.
John P. FISCHER, Jay Bradford FELL, James F. BLAKE, Ronald Jay HINKLIN, Macedonio J. MEJIA, Erik James HICKEN, Mark Joseph CHICARELLI, John J. GAUDINO, Guy P.A. VIGERS, Laurence E. BURGESS, Matthew Arnold MARX, James Gail CHRISTENSEN, Matthew Randolf LEE, Pavel SAVECHENKOV, Henry J. ZECCA, Tony P. TANG
Filed: 17 May 17
Utility
Quinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
2 Sep 21
The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
Filed: 13 Oct 20
Utility
Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same
26 Aug 21
The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer.
Allen Thomas Horhota, Young-Ho Song, Ujjwal Chaitanya Joshi, Nicholas Jon Boylan, Matthew John Simmons
Filed: 18 Feb 21
Utility
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
26 Aug 21
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof.
Wendy Jo Watson, Luis Pascual Jodar Martin-Montalvo, Raul Enrique Isturiz, Ralf Rene Reinert
Filed: 27 Apr 21
Utility
CDK2 Inhibitors
26 Aug 21
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 20 Apr 21
Utility
Methods of Treating Cancer Using Combination Therapy
19 Aug 21
The present application is directed to therapeutic regimens and methods of treating cancer, with the regimens and methods comprising administering to the subject a programmed death-ligand 1 (PD-L1) inhibitor and a recombinant vesicular stomatitis virus that has been engineered to expresses interferon beta (VSV-IFNβ-NIS).
Stephen J. Russell, Alice Bexon, Kah-Whye Peng, Rose Marie Diaz
Filed: 21 Jun 19
Utility
Anti-e-selectin Antibodies, Compositions and Methods of Use
12 Aug 21
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin.
James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
Filed: 21 Jan 21
Utility
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
29 Jul 21
Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
Filed: 3 Mar 21
Utility
Solid Dispersions of a ERB2 (HER2) Inhibitor
22 Jul 21
A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein.
David Shank Fry, Christopher M. Lindemann, Michael Preigh, Corey Jay Bloom, Christopher Donovan Craig, Devon Brevard Dubose, Jeff Gautschi, Dan Smithey
Filed: 23 Dec 20
Utility
Aqueous Formulation Comprising 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA
15 Jul 21
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-enyl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid.
James Joseph Hussey, Andrew Gilbert Bright
Filed: 4 Jun 19
Utility
Recombinant ROBO2 Proteins, Compositions, Methods and Uses Thereof
15 Jul 21
The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors.
Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
Filed: 17 Dec 20
Utility
Oral Solution Formulation
8 Jul 21
The present invention relates to an oral solution formulation or an oral powder for constitution comprising 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, or a lactate or malate salt thereof, and a buffer system comprising lactic acid or malic acid.
Ashwinkumar JAIN, Weili YU
Filed: 3 May 19
Utility
Stability-modulating Linkers for Use with Antibody Drug Conjugates
8 Jul 21
The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
Russell George DUSHIN, Pavel STROP, Magdalena Grazyna DORYWALSKA, Ludivine MOINE
Filed: 23 Feb 21
Utility
N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES Useful As CCR6 Inhibitors
8 Jul 21
Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, JR., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
Filed: 5 Mar 21
Utility
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
1 Jul 21
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof.
Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
Filed: 6 Mar 21
Utility
Combination Product for the Treatment of Cancer
1 Jul 21
Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
Filed: 19 Oct 18
Utility
Methods of Treating Metabolic Disease
1 Jul 21
The present invention further relates to methods for treating a disease of iron metabolism and disease of fat or carbohydrate metabolism using a BMP agonist or antagonist
Alexander Hal Drakesmith, João André Traila Arezes, Simon John Draper, Kirsty Anne McHugh, Fredrik Karpe, Nathan Denton, Orla Cunningham, Niall John Foy, Reema Jasuja
Filed: 6 Jun 19
Utility
Oligonucleotide Compositions and Methods of Use Thereof
1 Jul 21
Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof.
Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
Filed: 1 Jun 18
Utility
Chemical Compounds
24 Jun 21
Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
Filed: 18 Dec 20
Utility
Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same
24 Jun 21
The present disclosure generally relates to nanoparticles comprising an antibody, such as an anti-PD-1 antibody.
Stephen E. Zale
Filed: 10 Feb 17